ENSCW
Ensysce Biosciences, Inc.
OTCHealthcareBiotechnologyUS
Rating:B-
Company Profile
CEO
D. Lynn Kirkpatrick
IPO Date
2018-01-05
Sector
Healthcare
Industry
Biotechnology
Exchange
OTC
Country
US
Ensysce Biosciences, Inc.
CEO
D. Lynn Kirkpatrick
IPO Date
2018-01-05
Sector
Healthcare
Industry
Biotechnology
Exchange
OTC
Country
US
| 270,000 |
| $0.48 |
| 2 Mar 2023 | GOWER BOB G | director | P-Purchase | Acquired | 109,300 | $0.49 |
| 1 Feb 2023 | GOWER BOB G | director | P-Purchase | Acquired | 357,143 | $1.40 |
| 1 Feb 2023 | GOWER BOB G | director | A-Award | Acquired | 714,286 | $1.40 |
| 1 Jul 2021 | Carrera Eric | — | A-Award | Acquired | 30,000 | $11.50 |
| 1 Jul 2021 | Peng George | — | A-Award | Acquired | 15,000 | $11.50 |